Skip to main content

RBC Capital Remains a Buy on Zimmer Biomet Holdings (ZBH)

Tipranks - Tipranks - Thu Feb 12, 6:42AM CST

RBC Capital analyst Shagun Singh Chadha reiterated a Buy rating on Zimmer Biomet Holdings yesterday and set a price target of $101.00.

Valentine's Day Sale - 70% Off

Singh Chadha covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Boston Scientific, and Stryker. According to TipRanks, Singh Chadha has an average return of 1.3% and a 48.35% success rate on recommended stocks.

In addition to RBC Capital, Zimmer Biomet Holdings also received a Buy from TipRanks – PerPlexity’s PerPlexity Medical – Devices in a report issued today. However, on the same day, Canaccord Genuity reiterated a Hold rating on Zimmer Biomet Holdings (NYSE: ZBH).

See today’s best-performing stocks on TipRanks >>

Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2 billion and a net profit of $230.9 million. In comparison, last year the company earned a revenue of $1.82 billion and had a net profit of $249.1 million

Read More on ZBH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).